The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Strengths:
1. Major technological advance.
2. Positive user feedback. Proven clinical benefit.
3. FDA approved (for patients >12yrs).
4. Exclusive market access (HW).
5. Knowledgeable & experienced BOD.
6. Solid institutional investor base.
Weaknesses:
1. Unexpected Approval delay + change in mkt sentiment.
2. Lack of critical mass to ‘go it alone’.
3. Lack of BOD commercialisation expertise.
4. Poor PR/comms.
Opportunities:
1. Substantial new value market/s.
2. KOLs support/influence underway. Target hospitals identified.
3. PBM reimbursement at premium price (vs MRI).
4. Expansion into new disease areas.
5. Attraction of JV Partner/takeover/new funding.
Threats:
1. PBM reimbursement delays.
2. Investor fatigue. SP drift on no clear plans.
3. JV Partner plays hardball.
4. Funding agreed but on less favourable terms.
5. General production/quality control issues.
‘…buying this product in droves…’
!!
The process of securing business for new drugs/new technology in the US market has been well explained by other posters. Obtaining essential reimbursement codes is initially bureaucratic and time-consuming.
It does seem that every bit of good news is in the price:
Patent protected breakthrough technology - tick.
FDA Approval - tick.
Hatch - Waxman 5yr exclusivity - tick.
Few short termers dump.
No institutional enthusiasm for further investment.
Company seems to be in a PR-free zone.
So down goes the sp as if nothing’s happened.
There’s still about 90m shares held by the sub 3% ers, so a seller could have 5m-ish to get rid off and not notify.
The repeated block sells of 100k are definitely what’s keeping the lid on this.
Why sell at this low level? Dunno.
Thompi,
Sounds like we’re equally p!ssed off.
But in my case I’m more interested in the absence of any extra significant buying - even at these lower levels. The lack of comms has to be taken on trust : ie. Wallbrook has nothing sensible to say as the Company has nothing to give them!
It’s been just under a month since the FDA approval - which, although a binary event, was expected to be +ve by 99% of holders (imho) hence almost no selling prior to the event.
As people have suggested, it’s the absence of anything else + the prospect of a wait for Hatch- Waxman and probably even longer for reimbursement codes - but I believe that only three PBMs account for around 80% of the business, so it shouldn’t take for ever to negotiate an acceptable fee (but WDIK?).
When you look through the Board’s CVs you couldn’t wish for a more suitably qualified bunch
https://polarean.com/about-polarean-imaging/
What’s not clear to me is the infrastructure under it to help commercialise the technology.
Perhaps it’s better if one of the more established cos take the next step.
Bracco’s there, but perhaps the newly relaunched GE Healthcare also?
GLA
‘….Im beginning to suspect foul play by the management...AIMHO.....’
tomorrowtoday,
That’s a pretty ridiculous statement.
The Board undoubtedly hold many multiples of your own holding so would be damaging their own positions and those of even larger holders like Amati.
Also, Hullihen and others haven’t come this far to deliberately ****it up. True, they may have misjudged things and are now in a weakened position, but so are so many other small ‘biotech’ companies.
If nothing else, you’d think that the Board would be buying at these levels, given their previous history. So, since they’re not, it suggests that the near-term info they’re privy to precludes them from doing so.
Wonder what that could be?
:-/
burylad,
On the contrary, at the age of 97 Mr Butler has started posting rather late in life, but makes a valid point. But we each have our own ways of passing the time between RNS’s.
Personally, my investment here’s based on admiration for Dr Jourdan of Amati and respect for Richard Hullihen’s enthusiasm and professionalism as well, of course, as a desire to see this breakthrough technology benefit patients.
Anyway, what’s in an avatar…?!
;-)
GLA
Once ChatGPT’s with us, you’ll be pushed to know exactly who/what you’re talking to!
Anyway, Hullihen’s got 3.5m reasons for getting this right.
No press coverage? Too busy with Prince Happy’s brain- dump.
;-)
Sit tight.
https://m.youtube.com/watch?v=rWAZw3UKIJE
As posted by ‘twib’ below, this link explains completely why anyone would invest in this company. More specifically, why Amati continue to hold 25m shares and just how impressive the CEO is in his understanding and belief of the technology’s benefits for patients and specialists.
Sadly, imho, being two years old, it also hints at the ‘behind the scenes’ chaos that was building at the FDA as a result of Covid 19 restrictions and which came as such a shock to the evident confidence of the CEO and subsequent 12 month delay.
References to ‘a licence with GE’ aren’t clear to me, but perhaps can be revitalised due to recent approval.
30 mins well spent.